阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎临床疗效观察

doi:10.3969/j.issn.1672-5069.2014.06.008

摘要/Abstract

摘要： 目的探讨阿德福韦酯（ADV）联合苦参素治疗HBeAg阳性慢性乙型肝炎（CHB）患者的临床疗效及安全性。方法将80例确诊为HBeAg阳性的CHB患者随机分为对照组和治疗组,对照组40例使用ADV治疗,治疗组40例使用ADV联合苦参素治疗,两组均治疗12 m;在治疗3、6、9、12 m后,观察临床表现、血生化、血清HBV DNA载量、HBV血清学标志物变化及不良反应。结果在治疗6、9和12 m时,治疗组患者血清HBV DNA载量为（3.97±1.15） lg copies/ml、（3.38±1.24） lg copies/ml和（3.09±1.19）lg copies/ml,均显著低于对照组水平[（4.61±1.32）lg copies/ml、（4.17±1.12） lg copies/ml和（3.81±1.26）lg copies/ml,P<0.05];在3、6、9 m两组患者血清ALT水平无显著性差异,但均低于治疗前水平,在12 m时治疗组ALT为（30.1±15.4） U/L,显著低于对照组患者[（39.9±14.5）U/L,P<0.05];在治疗3 m时,两组间血清HBV DNA转阴率和ALT复常率无统计学差异,但在治疗6、9、12 m时,治疗组患者血清HBV DNA转阴率为55.0%、 65.0%和77.5%,显著高于对照组[32.5%、42.5%和57.5%,P<0.05）];在治疗9和12 m时,治疗组患者ALT复常率为82.5%和92.5%,显著高于对照组水平[60.0%和75.0%,P<0.05];在治疗12 m时,治疗组血清HBeAg阴转率及HBeAg血清学转换率分别为47.5%和42.5%,显著高于对照组[25.0%和20.0%,P<0.05];两组治疗期间未出现严重的不良反应。结论ADV联合苦参素治疗HBeAg阳性CHB患者临床疗效和安全性好。

关键词: 慢性乙型肝炎, 阿德福韦酯, 苦参素, HBeAg, 疗效

Abstract: Objective To investigate the efficacy and safety of adefovir dipivoxil combined with oxymatrine in the treatment of patients with HBeAg-positive chronic hepatitis B（CHB）. Methods Eighty patients with HBeAg-positive CHB were randomly divided into control group（n=40） and treatment group（n=40）. Patients in control group were treated with ADV,while patients in treatment group were treated with ADV combined with oxymatrine. All patients were treated for 12 months. At 3,6,9 and 12 month,symptoms and signs, serum biochemical parameters,serum HBV DNA levels,serological HBV markers and adverse events were observed. Results At 6,9 and 12 month,serum HBV DNA levels in treatment group were（3.97±1.15）lg copies/ml,（3.38±1.24） lg copies/ml and（3.09±1.19） lg copies/ml,significantly lower than in the controls[（4.61±1.32） lg copies/ml, （4.17±1.12） lg copies/ml and （3.81±1.26） lg copies/ml,respectively,P<0.05];serum alanine aminotransferase （ALT） levels at 3,6 and 9 m were similar between the two groups and were lower than in the pre-treatment levels; serum ALT levels in patients of treatment group at 12 m was（30.1±15.4） U/L,significantly lower than in the controls [（39.9±14.5）U/L,P<0.05];serum HBV DNA loss at 3 m and normalization rates of ALT level at 3 m and 6 m did not differ between the two groups,but the rates of HBV DNA loss in patients in treatment group at 6,9 and 12 m were 55.0%,65.0% and 77.5%,respectively,significantly higher than in the controls[32.5%,42.5% and 57.5%,respectively,P<0.05];normalization rates of ALT level of patients in treatment group at 9 and 12 m were 82.5% and 92.5%,significantly higher than in the controls[60.0% and 75.0%,respectively,P<0.05];negative rates and seroconversion rates of HBeAg for patients in treatment group at 12 m were 47.5% and 42.5%,respectively,significantly higher than in the controls[25.0% and 20.0%,respectively,P<0.05]. Serious adverse reactions did not occur during the treatment process in the two groups. ConclusionsADV combined with oxymatrine in treatment of patients with HBeAg-positive CHB is of good efficacy and safe.

Key words: Chronic hepatitis B, Adefovir dipivoxil, Oxymatrine, HBeAg, Efficacy

陈继红. 阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎临床疗效观察[J]. 实用肝脏病杂志, 2014, 17(6): 588-592.

Chen Jihong. Efficacy of adefovir dipivoxil combined with oxymatrine in the treatment of patients with HBeAg-positive chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 588-592.

参考文献

[1] 周清荣,张园海,申悦平. 苦参素治疗慢性乙型肝炎32例. 中西医结合肝病杂志,2003,13（3）:174-176.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[3] 任维鑫,柳梅,焦健. 恩替卡韦联合苦参素治疗慢性乙型肝炎48周疗效观察. 实用肝脏病杂志,2014,17（2）:184-185.
[4] 陈清,杨华芬. 拉米夫定联合苦参素治疗HBeAg 阳性慢性乙型肝炎70例. 中国中西医结合消化杂志,2010,18（2）:117-118.
[5] 余建国. 阿德福韦酯联合苦参素治疗慢性乙型肝炎临床观察. 实用肝脏病杂志,2011,14（6）:442-443.
[6] 李文琍,吴诗品. 阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的疗效观察. 中国临床药理学与治疗学,2007,12（7）:832-834.
[7] 茅益民,曾民德. 抗乙型病毒性肝炎新药—阿德福韦酯. 中华肝脏病杂志,2004,12（1）:61-63.
[8] 胡萌, 孙克伟. 阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎患者的临床研究. 中国中西医结合消化杂志,2012,20（4）:170-173.
[9] 张恒兵. 阿德福韦酯联合苦参素治疗HBeAg阳性慢性乙型肝炎疗效分析. 实用肝脏病杂志,2012,15（5）:440-441.
[10] 粱海林,聂苑霞,李琴,等. 苦参素葡萄糖注射液序贯苦参素胶囊治疗慢性乙型肝炎42例疗效观察. 肝脏,2005,10（1）:70-71.
[11] 宋宝君. 苦参素治疗慢性乙型肝炎的疗效观察. 世界中西医结合杂志,2009,4（4）:288-289.
[12] 李伟红. α-干扰素联合苦参素治疗HBeAg 阳性慢性乙型肝炎疗效观察. 实用肝脏病杂志,2014,17（2）:186-187.
[13] 顾锡炳, 杨小娟, 王栋, 等. 苦参素治疗慢性乙型肝炎患者T细胞亚群和细胞毒性T淋巴细胞的变化. 实用肝脏病杂志,2010,13（2）:128-129.
[14] 杨建功,辛建兰,何小峰. 苦参素治疗慢性乙型肝炎36例. 中西医结合肝病杂志,2005,15（5）:305-306.
[15] 杨炯,曾凤好. 替比夫定联合苦参素治疗HBeAg阳性慢性乙型肝炎43例. 中西医结合肝病杂志,2013,23（2）:114-115.